Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-Related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma ( RRMM): Final Data from the Phase 2 ELOQUENT-3 Trial

被引：2

作者：

Weisel, Katja ^{[1
]}

Dimopoulos, Meletios A. ^{[2
]}

San-Miguel, Jesus ^{[3
]}

Paner, Agne ^{[4
]}

Engelhardt, Monika ^{[5
]}

Taylor, Fiona ^{[6
]}

Lord-Bessen, Jennifer ^{[7
]}

Yao, David ^{[7
]}

Yip, Christine ^{[8
]}

Greenwood, Mike ^{[8
]}

Tang, Jackson ^{[7
]}

Cavo, Michele ^{[9
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany

[2] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

[3] Univ Navarra Clin, Pamplona, Spain

[4] Rush Univ Med Ctr, Chicago, IL USA

[5] Univ Med Ctr Freiburg, Freiburg, Germany

[6] Adelphi Values, Boston, MA USA

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Adelphi Values, Bollington, England

[9] Bologna Univ, IRCCS Azienda Osped Univ Bologna, Seragnoli Inst Hematol, Sch Med, Bologna, Italy

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-145310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1662

引用

页数：6

共 50 条

[31] Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
Chng, Wee-Joo
Li, Xinhua
Lin, Cindy
Kim, Jin Seok
Handa, Hiroshi
Durie, Brian G. M.
BLOOD, 2020, 136
[32] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Lonial, Sagar
Richardson, Paul
Reece, Donna
Mohamed, Hesham
Shelat, Suresh
San Miguel, Jesus
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
[33] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
Yashar, David
Spektor, Tanya M.
Martinez, Daisy
Ghermezi, Matthew
Swift, Regina A.
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Lim, Stephen
Vescio, Robert
Berenson, James R.
LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
[34] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
[35] Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[36] Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Dimopoulos, Meletios
Weisel, Katja
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
San Miguel, Jesus
Anderson, Kenneth
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna
Beksac, Meral
Shelat, Suresh
Sy, Oumar
Singhal, Anil
Richardson, Paul
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S253 - S253
[37] Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
Trudel, Suzanne
Beksac, Meral
Pour, Ludek
Delimpasi, Sosana
Quach, Hang
Vorobyev, Vladimir I.
Cavo, Michele
Suzuki, Kazuhito
Robak, Pawel
Morris, Kristin
Phillips-Jones, Amy
Zhou, Xiaoou Linnette
Fulci, Giulia
Sule, Neal
Kremer, Brandon
Opalinska, Joanna
Mateos, Maria-Victoria
Dimopoulos, Meletios Athanasios
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA105 - LBA105
[38] A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial
Ichinohe T.
Kuroda Y.
Okamoto S.
Matsue K.
Iida S.
Sunami K.
Komeno T.
Suzuki K.
Ando K.
Taniwaki M.
Tobinai K.
Chou T.
Kaneko H.
Iwasaki H.
Uemura C.
Tamakoshi H.
Zaki M.H.
Doerr T.
Hagiwara S.
Experimental Hematology & Oncology, 5 (1)
[39] Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma
Dimopoulos, Meletios
Weisel, Katja
Hungria, Vania
Sapra, Sandhya
Sule, Neal
Li, Mary
McKeown, Astrid
Kazeem, Gbenga
Polinkovsky, Margaret
Meunier, Juliette
Loubert, Angely
Bunod, Laurine
Perera, Sue
Currie, Brooke
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S174 - S175
[40] Phase 1b Study of Daratumumab plus Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM) with ≥2 Prior Lines of Therapy
Chari, Ajai
Suvannasankha, Attaya
Fay, Joseph
Arnulf, Bertrand
Kaufman, Jonathan L.
Ifthikharuddin, Jainulabdeen
Weiss, Brendan M.
Krishnan, Amrita
Lentzsch, Suzanne
Comenzo, Ray
Wang, Jim
Masterson, Tara
Nottage, Kerri
Schecter, Jordan
Chiu, Christopher
Khokhar, Nushmia
Ahmadi, Tahamtan
Lonial, Sagar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E14 - E15

← 1 2 3 4 5 →